

Nathan Alhalel, MD, MPH¹, Ralph Alhalel, MD, AGAF² (1) Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco; (2) Rio Grande Gastroenterology Consultants, McAllen, TX


Introduction

- Follicular lymphoma (FL) accounts for approximately 4% of gastrointestinal (GI) lymphomas.¹
- Of the follicular lymphomas found in the GI tract, duodenal-type follicular lymphoma (D-FL) make up 63-89% of cases.^{2,3}
- D-FL is often incidentally discovered, lacks invasion into deeper layers of the GI tract, and indolent in nature.⁴
- The Lugano staging classification is recommended for staging and prognosis. D-FL 5-year overall survival and progression free survival rate is 100% and >90%, respectively.^{3,5}
- Due to these unique characteristics, D-FL is recognized as a distinct variant of follicular lymphoma in the World Health Organization (WHO) classifications.^{5,6}
- Given the excellent prognosis and rare occurrence of progression to high stage FL or transformation to diffuse large B cell lymphoma, a "watch and wait" therapeutic approach is often taken.^{4,7,8,9}

Case Description

- A 39-year-old female with no pertinent past medical history presented with refractory dyspepsia. She denied any fevers, chills, night sweats, fatigue, weight loss, nausea, vomiting, diarrhea, melena, or hematochezia.
- Her endoscopy was notable for gastritis, duodenal atrophy, and three 5-mm pale nodules in the second part of the duodenum (Figures 1A-C).
- Initial biopsy of these polyps showed atypical lymphoid follicular aggregates. Outside pathologists' subsequent review noted atypical lymphoid cells positive for CD10, BCL-2, BCL-6, and CD20 markers (Figures 2A, 2B), consistent with duodenal-type follicular lymphoma.
- Additional workup:
 - LDH, SPEP with immunofixation, HIV/HBV/HCV serologies were negative.
 - Full body CT and PET-CT showed no evidence of metabolically active lymphoma elsewhere in the body.
 - Antegrade small bowel enteroscopy to the mid-jejunum and colonoscopy were unremarkable.
- Per the Lugano staging system for gastrointestinal lymphomas, the patient was diagnosed with stage I (confined to the gastrointestinal tract) D-FL, and a "watch and wait" approach was recommended by Oncology.

Multifocal Duodenal-type Follicular Lymphoma Found Incidentally on Diagnostic Endoscopy: A Case Report and Literature Review






Figure 1A-1C: Endoscopic images of the duodenal second portion. Three distinct 5-mm pale nodules were seen and biopsies. First, second, and third lesions are seen in figure 1A 1B, and 1C, respectively.






Figure 2A,2B: Duodenal biopsy include fragments with an atypical lymphoid infiltrate, comprised of a majority of small cells, without significant mitotic activity or cellular atypia. Immunohistochemical stains for CD10, BCL-2, BCL-6, and CD20 are positive in atypical follicles.

Endoscopy





- incidentally diagnosed on EGD.
- Endoscopic Findings:
 - portion of the duodenum.³⁻⁴
 - endoscopy.³
- \bullet treatment.
- disease.4,7

- the "watch and wait" treatment strategy.⁸

- Surg Pathol. 2011;35(9): 1255–1263.

- on outcome. Leuk Lymphoma. 2013; 54(1):177–180
- lymphoma. J Gastroenterol Hepatol. 2018;33(8):1461–1468.
- lymphoma. Ann Oncol. 2010;21:1500–1505.

Discussion

• As in our case, most patients do not have symptoms attributable to D-FL and are

• D-FL most often presents with multiple low-stage, white nodules in the second

• Additional lesions are found in the remaining small bowel in 85% of D-FL cases, warranting thorough small bowel assessment with enteroscopy or capsule

• Gastric and/or colorectal involvement is exceedingly rare.^{3,4}

Treatment options include "watch and wait", chemotherapy, radiation, chemotherapy plus radiation, or surgical resection. However, there is no consensus on first-line

Though radiation therapy and/or chemotherapy leads to higher rates of clinical remission, it does not result in a clinically significant reduction in progressive

Radiation therapy is limited by the difficulty in identifying further involvement in the rest of the small bowel to effectively radiate all lesions.⁹

Based on many retrospective case series, it appears "watch and wait" is a reasonable approach for asymptomatic D-FL without nodal or systemic spread.^{2,4,7-9}

There is no evidence regarding the optimal surveillance interval for patients under

Future studies with longer duration of follow up and variable surveillance strategies are needed to better understand the natural course of D-FL.

References

Armitage JO, Weisenburger DD. New approach to classifying nonHodgkin's lymphomas: clinical features of the major histologic subtypes: NonHodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795. 2. Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, Ferry JA. Primary follicular lymphoma of the gastrointestinal tract. Am J

Takata K, Okada H, Ohmiya N, et al. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: a multicenter, retrospective analysis in Japan. Cancer Sci. 2011;102(8):1532–1536.

^{4.} Montes-Moreno, S., King, R.L., Oschlies, I. et al. Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. Virchows Arch 2020;476: 667–681.

^{5.} Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct

mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;29(11):1445–1451. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors . 4thed. Lyon: International Agency for Research on Cancer: WHO classification of tumours of haematopoietic and lymphoid tissues; 2017.

[.] Kiess AP, Yahalom J. Primary follicular lymphoma of the gastrointestinal tract: effect of stage, symptoms and treatment choice

Tari A, Kitadai Y, Mouri R, Takigawa H, Asaoku H, Mihara K, Takata K, Fujihara M, Yoshino T, Koga T, Fujimori S, Tanaka S, Chayama K. Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular

Mori M, Kobayashi Y, Maeshima AM, et al. The indolent course and high incidence of t(14;18) in primary duodenal follicular